Advancing Endotoxin Detection: The Rise of USP Chapter <86> and Recombinant Reagents

[Article Title]

Endotoxin detection is vital for pharmaceutical safety. While traditional methods have depended on animal-based testing, the industry is undergoing a significant shift with the rise of recombinant technologies and updates reflected in USP Chapter <86>.

In a recent webinar led by Holly Kabrick, Product Manager at Lonza, expert Allen L. Burgenson discussed the shift toward recombinant technologies, including recombinant Factor C assays, and the impact of USP <86>. This article highlights key insights on the evolving science and regulatory future of pyrogen testing. Download the article to explore developments in recombinant testing, validation challenges, regulatory expectations, and more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.